|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
The immune checkpoint inhibitors (ICPIs) agents anti-T lymphocytes-associated antigen 4 (CTLA-4) and anti-programmed cell death protein-1 (PD-1) and its ligands (PD-L1/PD-L2) have opened a new scenario in the treatment of cancer.
|
31542865 |
2020 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression |
BEFREE |
Taken together, we identify a super-enhancer (PD-L1L2-SE) that is responsible for the overexpression of PD-L1 and PD-L2 as well as immune evasion in cancer.
|
31825827 |
2019 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Gastric mast cells express the programmed death ligands (PD-L1 and PD-L2) which are relevant as immune checkpoints in cancer.
|
31035644 |
2019 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Programmed cell death ligand-1 (PD-L1) and ligand-2 (PD-L2) interaction with programmed cell death protein-1 (PD-1) represent an immune-inhibiting checkpoint mediating immune evasion and is, accordingly, an important target for blockade-based immunotherapy in cancer.
|
31159869 |
2019 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression |
BEFREE |
A significant association of PD-L2 expression above the COP (positive) with malignancy was ascertained (P < 0.001).
|
30659749 |
2019 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
<b>Methods:</b> We analyzed the methylation at different CpG sites within the PD-L2-encoding gene <i>PDCD1LG2</i> with regard to correlations and associations with gene expression, clinicopathological parameters, molecular features and immune cell infiltrates in two publicly available cohorts (The Cancer Genome Atlas and Singapore cohorts) of a total of 594 gastric adenocarcinoma patients.
|
30821175 |
2019 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
We identified spontaneous specific T-cell reactivity against two epitopes located in the signal peptide of PD-L2 from samples from patients with cancer as well as healthy individuals ex vivo.
|
29308318 |
2018 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
When surface expression of the inhibitory ligands PDL1 and PDL2 was assessed, monocytes exposed to both cancer cell lines and to live mf significantly upregulated PDL1 and PDL2 expression.
|
29668679 |
2018 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Thus, tumor PDCD1LG2 expression is inversely associated with Crohn-like lymphoid reaction to colorectal cancer, suggesting a possible role of PDCD1LG2-expressing tumor cells in inhibiting the development of tertiary lymphoid tissues during colorectal carcinogenesis.<i>Cancer </i>.
|
29038297 |
2017 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Blocking programmed cell death protein (PD)-1 signaling, which mediates T cell suppression via engagement of its inhibitory ligands, PD-L1 or PD-L2, is of particular interest due to recent successes in many types of cancer.
|
28539588 |
2017 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression |
BEFREE |
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
|
28619999 |
2017 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Immune checkpoint blockade therapeutics, notably antibodies targeting the programmed death 1 (PD-1) receptor and its PD-L1 and PD-L2 ligands, are currently revolutionizing the treatment of cancer.
|
28402953 |
2017 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
These partially differentiated PD-1<sup>+</sup> polyfunctional TILs have a high capacity for persistence and may be susceptible to PD-L1/PD-L2-mediated inhibition.<i>Clin Cancer Res; 23(19); 5779-88.©2017 AACR</i>.
|
28679768 |
2017 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
This catalog of recurrent alterations helps identify adaptations such as PD-L2 operative tumor cell intrinsically and/or extrinsically early on therapy.<i>Cancer Discov; 7(11); 1248-65.
|
28864476 |
2017 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Last, focal copy-number gain of chromosome 9p24 including the genes CD274 (PD-L1) and PDCD1LG2 (PD-L2) was noted in three cases, which represents a well-described mechanism of immune evasion in cancer.
|
26564005 |
2016 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
These data suggest a potential role for PD-L2 inhibition and immune modulation as treatment for patients with ACC.Cancer .
|
27312343 |
2016 |
|
PDCD1LG2
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Tumor PD-L1 expression reflects an immune-active microenvironment and, while associated other immunosuppressive molecules, including PD-1 and PD-L2, is the single factor most closely correlated with response to anti-PD-1 blockade.Clin Cancer Res; 20(19); 5064-74.©2014 AACR.
|
24714771 |
2014 |